Johnson & Johnson (NYSE:JNJ) Shares Sold by SeaBridge Investment Advisors LLC

SeaBridge Investment Advisors LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 30.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,030 shares of the company’s stock after selling 2,200 shares during the period. SeaBridge Investment Advisors LLC’s holdings in Johnson & Johnson were worth $788,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in JNJ. Hibernia Wealth Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $27,000. FNY Investment Advisers LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at approximately $37,000. Tower View Wealth Management LLC lifted its stake in Johnson & Johnson by 183.3% in the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 165 shares in the last quarter. Creative Capital Management Investments LLC lifted its stake in Johnson & Johnson by 43.0% in the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

JNJ opened at $148.78 on Friday. The company’s 50-day moving average price is $157.42 and its 200 day moving average price is $156.08. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The firm has a market cap of $358.53 billion, a price-to-earnings ratio of 10.77, a price-to-earnings-growth ratio of 2.55 and a beta of 0.53. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same quarter last year, the business earned $2.35 earnings per share. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. As a group, sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Morgan Stanley dropped their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James upped their price objective on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $177.31.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.